Back to results
US 10,376,508 B2Granted
Liposomal ciprofloxacin formulations with activity against non-tuberculous mycobacteria
AssigneesAradigm Corporation, Oregon State University
InventorsIgor Gonda, James Blanchard, David C. Cipolla, Luiz Eduardo Moreira Bermudez
Life of this patent
Estimating the term…
Abstract
Methods of treatment of NTM lung infections using formulations of liposomal ciprofloxacin. Specific liposome formulations and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.
Claims16
A method of treating an antibiotic resistant infection in a patient, comprising:
- aerosolizing a formulation comprising free ciprofloxacin and ciprofloxacin encapsulated in liposomes;
- and
- inhaling the aerosol into the patient's lungs whereby 90% or more of the liposomes maintain structural integrity after being aerosolized and after contacting lung tissue provide a ciprofloxacin release rate of 0.5% to 10% per hour,
- wherein the antibiotic resistant infection comprises microorganisms in a biofilm in the lung of the patient and the liposomes release drug over a period of time and at a rate effective in treating a biofilm infection;
- wherein the liposomes comprise a cryopreservative and a surfactant and have an average particle size of about 75 nm to about 120 nm and are unilamellar.
2 more elements
A method of treatment, comprising:
- aerosolizing a formulation to create aerosolized particles having an aerodynamic diameter in a range of from 1 micron to 12 microns;
- wherein the aerosolized formulation comprises:
- a liquid carrier comprising ciprofloxacin at a concentration of 20 mg/mL to 80 mg/mL of ciprofloxacin in solution,
- liposome unencapsulated ciprofloxacin in solution;
- and ciprofloxacin as nanocrystals encapsulated inside the liposomes, wherein nanocrystals in the liposomes have a dimension of 10 nanometers;
- inhaling the aerosol into the patient's lungs whereby 90% or more of the liposomes maintain structural integrity after being aerosolized and after contacting lung tissue provide a ciprofloxacin release rate of 0.5% to 10% per hour,
- whereby an antibiotic resistant infection comprises microorganisms in a biofilm in the lung of the patient, and the liposomes release drug over a period of time and at a rate effective in treating the biofilm infection;
- wherein the liposomes comprise a cryopreservative and a surfactant and have an average particle size of about 75 nm to about 120 nm and are unilamellar.
5 more elements
A method of treating an antibiotic resistant infection in a patient, comprising:
- aerosolizing a formulation comprising free ciprofloxacin and ciprofloxacin encapsulated in liposomes;
- and
- inhaling the aerosol into the patient's lungs whereby 90% or more of the liposomes maintain structural integrity after being aerosolized and after contacting lung tissue provide a ciprofloxacin release rate of 0.5% to 10% per hour,
- wherein the antibiotic resistant infection comprises microorganisms in a biofilm in the lung of the patient and the liposomes release drug over a period of time and at a rate effective in treating a biofilm infection;
- wherein the liposomes comprise a cryopreservative and a surfactant and have an average particle size of about 75 nm to about 120 nm and are unilamellar;
- wherein:
- the aerosolizing and inhaling are repeated once each day over a period of seven days to fifty-six days.
4 more elements
Dependencies are inferred from the claim text.